Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Results were consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and ...
Business Insider26d
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
“C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life,” said Lydia Abad-Franch, M.D., head ...
Pharmabiz24d
Sobi & Apellis Pharma announces EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN
“C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life,” said Lydia Abad-Franch MD, head of R&D and ...
Finanznachrichten26d
Swedish Orphan Biovitrum AB: EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN
"C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life," said Lydia Abad-Franch MD, Head of R&D ...
Yahoo Finance26d
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has ...